Roivant Sciences revenue and financials
$35.53Change from previous close: −0.70%Absolute change: −$0.25
In the fiscal year ended March 2026, Roivant Sciences reported revenue of $8.26M (−71.57% year over year). The net loss was $299.77M.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −71.57%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3,629.2%
- FY to Mar 2025: -592.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 5,709 | 5,437 | 7,222 | 2,390 | 2,585 |
| Current assets | 5,167 | 5,000 | 6,732 | 1,799 | 2,147 |
| Cash and equivalents | 1,419 | 2,715 | 6,495 | 1,677 | 2,060 |
| Short-term investments | 2,873 | 2,171 | 0.0 | — | — |
| Receivables | 770 | 0.0 | 82.8 | 37.6 | 6.7 |
| Inventory | — | — | 35.3 | 2.8 | 0.0 |
| Net property, plant and equipment | 92.4 | 101 | 59.3 | 92.3 | 86.9 |
| Other intangible assets | — | — | — | 145 | — |
| Long-term investments | 408 | 303 | 248 | 304 | 326 |
| Current liabilities | 281 | 149 | 267 | 272 | 184 |
| Accounts payable | 18.0 | 23.7 | 14.0 | 37.8 | 34.6 |
| Long-term debt | — | — | 431 | 376 | 210 |
| Total debt | 107 | 100 | 54.0 | 481 | — |
| Total liabilities | 416 | 250 | 774 | 782 | 524 |
| Total equity (incl. minority) | 5,292 | 5,187 | 6,449 | 1,608 | 2,061 |
| Retained earnings | -502 | 116 | 576 | -3,773 | -2,764 |
| Minority interest | 765 | 500 | 480 | 450 | 404 |